相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Towards personalized treatment for early stage HER2-positive breast cancer
Kristina Goutsouliak et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2020)
DNA methylation in breast cancers: Differences based on estrogen receptor status and recurrence
Kristin E. Williams et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2019)
Patterns of breast cancer relapse in accordance to biological subtype
Atanas Ignatov et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2018)
Breast tumor cell-specific knockout of Twist1 inhibits cancer cell plasticity, dissemination, and lung metastasis in mice
Yixiang Xu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib
Lisa A. Carey et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Luminal Progenitors Restrict Their Lineage Potential during Mammary Gland Development
Veronica Rodilla et al.
PLOS BIOLOGY (2015)
Two histopathologically different diseases: hormone receptor-positive and hormone receptor-negative tumors in HER2-positive breast cancer
Hee Jin Lee et al.
BREAST CANCER RESEARCH AND TREATMENT (2014)
Scalable control of mounting and attack by Esr1+ neurons in the ventromedial hypothalamus
Hyosang Lee et al.
NATURE (2014)
Clinically Used Breast Cancer Markers Such As Estrogen Receptor, Progesterone Receptor, and Human Epidermal Growth Factor Receptor 2 Are Unstable Throughout Tumor Progression
Linda Sofie Lindstrom et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial
Jose Baselga et al.
LANCET (2012)
Stability of Estrogen Receptor Status in Breast Carcinoma A Comparison Between Primary and Metastatic Tumors With Regard to Disease Course and Intervening Systemic Therapy
Yun Gong et al.
CANCER (2011)
FOXA1 is an essential determinant of ERα expression and mammary ductal morphogenesis
Gina M. Bernardo et al.
DEVELOPMENT (2010)
Metastatic Behavior of Breast Cancer Subtypes
Hagen Kennecke et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Disruption of the SRC-1 gene in mice suppresses breast cancer metastasis without affecting primary tumor formation
Shu Wang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function
Suleiman Massarweh et al.
CANCER RESEARCH (2008)
Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the arimidex, tamoxifen, alone or in combination trial
Mitch Dowsett et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Positive cross-regulatory loop ties GATA-3 to estrogen receptor α expression in breast cancer
Jerome Eeckhoute et al.
CANCER RESEARCH (2007)
Faithful activation of an extra-bright red fluorescent protein in knock-in Cre-reporter mice ideally suited for lineage tracing studies
Herve Luche et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2007)
Introduction of oncogenes into mammary glands in vivo with an avian retroviral vector initiates and promotes carcinogenesis in mouse models
Zhijun Du et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival:: an overview of the randomised trials
O Abe et al.
LANCET (2005)
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer
MJ Piccart-Gebhart et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival:: an overview of the randomised trials
O Abe et al.
LANCET (2005)
Molecular changes in tamoxifen-resistant breast cancer: Relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase
MC Gutierrez et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance
R Schiff et al.
CLINICAL CANCER RESEARCH (2004)
分享论文
